TrumpRx Launches to Provide Recued Prices for Prescription Medicines in the U.S.
President Donald Trump has formally launched the TrumpRx website, a new platform designed to provide significantly reduced prices on prescription
Read more
Regulatory
FDA Approves Novo’s Wegovy® Pill as First Oral GLP-1 Weight Loss Therapy
Novo Nordisk A/S has announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral
Read more
Merck’s KEYTRUDA QLEX™ Secures FDA Approval as First Subcutaneous Pembrolizumab Injection
Merck & Co., known as MSD outside of the United States and Canada, announced on Saturday that the U.S. Food
Read more
FDA Approves J&J’s Inlexzo™ Breakthrough Bladder Cancer Therapy
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved INLEXZO™ (gemcitabine intravesical system), a
Read more
Boehringer’s HERNEXEOS® Wins Accelerated FDA Nod in Lung Cancer
In a landmark decision for HER2-mutant lung cancer, the US FDA has granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® (zongertinib),
Read more
Novartis Gains First-ever Approval for Infant Malaria Medicine
In a breakthrough for pediatric malaria treatment, Novartis has received approval from Swissmedic for Coartem® (artemether-lumefantrine) Baby, marking the first-ever
Read more
FDA Approves Gilead’s Yeztugo® (Lenacapavir) as First Biannual Injectable HIV PrEP
Gilead Sciences, Inc. (Nasdaq: GILD) has announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir) as
Read more
Novartis Secures Landmark FDA Approval for Fabhalta® in Rare Kidney Disease
Novartis has received its third U.S. Food and Drug Administration (FDA) approval for Fabhalta® (iptacopan), marking a major milestone as
Read more
Driving Efficiency and Compliance in Pharma with SenseAnywhere’s Next-Gen Temperature Monitoring Solutions
In today’s strictly regulated pharmaceutical industry, the need for temperature monitoring solutions is paramount. The quality, reliability, and durability of
Read more
Pfizer’s ADCETRIS® Approved by FDA for Relapsed or Refractory Large B-Cell Lymphoma
Pfizer announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) in combination with
Read more